‘Remarkable’ tolerability observed with asciminib in a heavily pretreated real-world CML-CP population
An Italian real-world study assessed the use of asciminib in a compassionate use setting in heavily pretreated patients with chronic-phase.
China NMPA grants Breakthrough Therapy Designation for mesutoclax in MCL
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation for.
Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances
Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, and Gwen Nichols, MD, CMO of the Leukemia.
Study identifies nonmutational p53 dysfunction as MDS risk factor
Even in patients with myelodysplastic syndromes (MDS) who don’t have a mutation in tumor protein 53 (p53), the p53 protein.
Top Categories
POPULAR NEWS
Abstract submissions now open for SOHO 2025
February 14, 2025
NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
January 3, 2025
Asciminib benefit-risk profile bests other TKIs in CML
December 10, 2024
Meetings
Editorial Board
Join Us Today and Become a Part of the SOHO Community
- Instant connections to our SOHO Communityof nearly 9,000 members
- Access to a comprehensive Resource Centerthat includes slides, publications, abstracts, videos & more
- Connection to our SOHO DocMatter Communityfor hematologic oncology discussions and education
- Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
- Free online and print subscription (US members) to our news publication,'SOHO Insider'
- Significant member-only discounts on meetings and events
- Early member-only registration and housing opportunities
- ... and much more!
SOHO Career Center
- Create a job seeker profile
- Perform intuitive searches for new jobs
- Auto-fill your resume through uploaded files
- Apply to new jobs through a streamlined workflow
- Receive email alerts when new relevant jobs are posted
To access the SOHO Career Center click the following link.
